From: Modelling the cost-effectiveness of pay-for-performance in primary care in the UK
Variable | Base-case value | Sensitivity analysis range | ICER at low value | ICER at high value |
---|---|---|---|---|
Adjusted QOF mortality benefit (for those aged > 40 years with CVD) | 58.93 | −130.57 to 12.81 | QOF dominated | £20,044/QALY |
CVD prevalence, males (aged 45–64 years, aged 65–74 years) | 14.6%, 28.5% | ±20% | £49,266/QALY | £49,485/QALY |
CVD prevalence, females (aged 45–64 years, aged 65–74 years) | 8.4%, 22.5% | ±20% | £49,302/QALY | £49,414/QALY |
CVD mortality multiplier (male, female) | 1.6, 2.1 | ±20% | £47,246/QALY | £51,249/QALY |
CVD utility | 0.796 | ±20% | £43,516/QALY | £64,805/QALY |
Acute CVD event costs (i.e. costs within first year of CVD event) | £10,871 | ±20% | £49,850/QALY | £48,874/QALY |
Chronic CVD event costs (i.e. annual costs for all years after first year) | £3282 | ±20% | £50,350/QALY | £48,375/QALY |
Average NHS costs by age | Age-based table | £0 to +100% | £46,270/QALY | £52,455/QALY |
Discount rate | 3.5% | 0–5% | £38,337/QALY | £54,587/QALY |